Immunoassay screen for the following drug classes or method groups: barbiturates, cannabinoids, cocaine, and ethanol. Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
Results of this test are presumptive. If confirmatory testing is desired, the confirmatory test(s) can be ordered as add-on (u-have) tests, utilizing the original urine collection, within 9 days of the original test.
This test is intended to compliment the test “Targeted Drug Panel, Urine” (TDPU).
Slapped Cheek disease
NOTE: This test is only for internal use only. It is active in the Lab System only – and will need to be manually entered via LOM if needed.
PD-L1, PDL1, 22C3, KEYTRUDA, pembrolizumab, IHC, Immunohistochemistry
blood pH, arterial pH
blood pH, venous pH
Phenylalanine Includes Tyrosine PKU (Phenylketonuria) Tyrosine Tyrosinemia Hyperphenylalaninemia
+3/+7+9/+1513q- / -13 (13q deletion) or RB117p- (17p deletion) or TP53-13 (monosomy 13)IGH (14q32) rearrangementMonoclonal Gammopathy of Unknown Significance (MGUS)Multiple MyelomaMYC (8q24.1) rearrangementPlasma Cell Leukemiat(4;14) - FGFR3/IGHt(6;14) - CCND3/IGHt(11;14) - CCND1/IGHt(14;16) - IGH/MAFt(14;20) - IGH/MAFB+1q or 1q22
PLM, PLM6S, Platelet Mapping ADP, Platelet Mapping AA
HKH-MA, ActFMA, ADP-MA, %INH-ADP, %AGG-ADP, AA-MA, %INH-AA, %AGG-AA
JAK2 exon 12
Myeloproliferative Neoplasm (MPN)
Both DNA and RNA are extracted. The algorithm starts with a highly sensitive DNA-based JAK2 V617F test by allele specific polymerase chain reaction. If the JAK2 V617F result is negative or very low positive (0.06%-0.6%), JAK2 exon 12-15 Sanger sequencing test will be performed on the stored RNA sample. If a JAK2 V617F mutation (>0.6%) is detected, the algorithm stops and no further testing will be performed.
The Sanger sequencing covers JAK2 exons 12 through the first 90% of exon 15, which spans the region containing essentially all mutations reported in myeloproliferative neoplasms. The following algorithms are available in Special Instructions.
Acute Intermittent Porphyria (AIP) Hereditary Coproporphyria (HCP) PBG (Porphobilinogen) Variegate Porphyria (VP)
Porphobilinogen Qnt, U (PBGU)
Acute Intermittent Porphyria (AIP) Congenital Erythropoietic Porphyria (CEP) Coproporphyrin Hereditary Coproporphyria (HCP) PBG (Porphobilinogen) Porphyria Cutanea Tarda (PCT) Porphyrins, Fractionation, Urine Uroporphyrin Variegate Porphyria (VP)
Prostate Specific Antigen, Total Hybritech
ETC, Mitochondrial Electron Transport Chain Defects, Mitochondrial Respiratory Chain Disorders, PC, PDH (Pyruvate Dehydrogenase) Deficiency, PDHC (Pyruvate Dehydrogenase Complex), Pyruvate, Pyruvate Carboxylase Deficiency, Pyruvate Dehydrogenase (PDH) Deficiency, Pyruvate Dehydrogenase Complex (PDHC)
Pyruvate, Spinal Fluid